Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia

The Food and Drug Administration currently approves the combination of hypomethylating agents (HMA), azacytidine or decitabine with venetoclax (VEN) for acute myeloid leukemia (AML) patients aged more than 75 years and for patients unsuitable for intensive chemotherapy. The risk of fungal infection...

Descripción completa

Detalles Bibliográficos
Autores principales: De Gregori, Simona, Gelli, Eleonora, Capone, Mara, Gambini, Giulia, Roncoroni, Elisa, Rossi, Marianna, Tobar Cabrera, Claudia Patricia, Martini, Gianluca, Calabretta, Ludovica, Arcaini, Luca, Albertini, Riccardo, Zappasodi, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303160/
https://www.ncbi.nlm.nih.gov/pubmed/37376128
http://dx.doi.org/10.3390/pharmaceutics15061680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303160/
https://www.ncbi.nlm.nih.gov/pubmed/37376128
http://dx.doi.org/10.3390/pharmaceutics15061680

Ejemplares similares